Mild cognitive impairment (MCI) is a popular topic in the literature on aging and dementia. This condition refers to persons who are slightly cognitively impaired for age but do not meet the criteria for dementia. Many longitudinal studies addressing these persons are underway, and data are emerging regarding neuroimaging features and the underlying neuropathology of MCI. Clinical trials are being conducted to determine if any treatments might be effective at preventing the progression to dementia.
OVERVIEW
Recently, increasing attention has been paid to the milder end of the spectrum of cognitive impairment. Individuals who ultimately develop a degenerative dementia such as Alzheimer's disease (AD) likely transition through a period of mild impairment. This transitional zone has been described by authors using a variety of terms such as mild cognitive impairment, dementia prodrome, incipient dementia, and isolated memory impairment, among others (Petersen et al, 2001a) . The term mild cognitive impairment (MCI) will be used in the current discussion. The following presentation will discuss the definition of MCI, outline its natural history, assess various prediction factors, speculate on the neuropathologic substrate, and discuss current challenges pertaining to the concept.
BACKGROUND
Inherent in the discussion of normal aging and transitional stages to AD is the question, ''What is normal?'' While this question is seemingly straightforward, its precise answer can be elusive. There can be multiple semantic definitions of the term normal. For the present discussion, two definitions of normal will be entertained.
One definition of normal concerns the optimal conditions in aging. In successful or healthy aging, there is likely very little cognitive decline over one's life span. These individuals typically are devoid of systemic illnesses or neurologic conditions that may compromise their function. In this setting, cognitive function can be preserved well into the 10th decade and perhaps beyond. However, this definition of normal pertains to a very small segment of the population. It is much more common to encounter individuals who have comorbidities as a part of aging. Consequently, another definition of normal might constitute what has been referred to as typical normal. This latter definition refers to the aging process in the context of other coexisting diseases such as hypertension, coronary artery disease, and sensory abnormalities. As is demonstrated in Case 1-1, often these persons will experience forgetfulness for names and will misplace objects. However, important information is retained, and these inconveniences do not impact their daily function. It becomes very difficult to determine to what extent these other comorbidities contribute to alterations that may be seen in cognitive function as a part of normal aging. The present discussion will use this latter definition of normal. Since the intent of this discussion is to describe situations that the clinician may encounter frequently, we will refer to normal subjects who may have coexisting medical conditions, but these disorders and their treatments are not felt to affect cognitive function.
Cognitive Continuum
The diagnosis of definite AD is made by neuropathologic confirmation at autopsy using standard criteria (National Institute on Aging, 1997) . In recent years, clinical-pathologic series have demonstrated good correspondence between the diagnosis of clinically probable AD and subsequent neuropathologic corroboration. As shown in this hypothetical depiction of function versus age in Figure 1 -1, the current challenge is to move to the left on the function curve to allow clinicians to make the diagnosis of a cognitive impairment before the patient reaches the threshold for clinically probable AD. This transitional zone between normal function and clinically probable AD has been characterized as MCI.
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Case 1-1
A 62-year-old man noted increasing difficulty recalling names of acquaintances. He had been retired for 3 years and now was aware of increasing trouble recalling the names of his former colleagues when he would unexpectedly meet them on the street. He was also aware of misplacing his car keys and reading glasses while at home. However, he had no difficulty remembering important events or appointments. In conversation, he recalled details of recent events quite well. A baseball fan, he could recount the fate of his favorite team virtually play-by-play for the past few games. His family and friends were not aware of him having any significant memory difficulties. He handled the family investments without problems. He had sought advice from his neurologist to determine whether he should be concerned about these symptoms.
Comment. This person is probably experiencing the slight cognitive changes of normal aging. He is somewhat forgetful, but this appears to be due to inattention. When he tries to remember a recent event, he is successful. This implies that the medial temporal lobe memory circuits are probably functioning well, and he needs to concentrate better at the time of learning. However, the most important fact is that he is still able to learn and remember recently experienced information. His symptoms are probably not pathologic.
KEY POINTS:
A The current challenge is to move to the left on the function curve in Figure 1-1 A Memory is perhaps the neuropsychological function that has been best studied in MCI.
FIGURE 1-1 Hypothetical characterization of function by age. As function declines, subjects go through a transitional stage of mild cognitive impairment prior to reaching the threshold for the diagnosis of clinically probable Alzheimer's disease (AD).
An alternative way of characterizing this continuum is shown in Figure  1 -2. This notion implies that those individuals who have ultimately become demented, presumably on a degenerative basis, will have passed through a stage of milder impairment. As Figure  1 -2 demonstrates, the border between MCI and normal aging is blurred. Intentional overlap is depicted in this figure since the precise delineation of this distinction is arbitrary. By the same token, there is overlap between MCI and dementia. Here again, the precise demarcation between MCI and dementia is also arbitrary. For communication purposes, we need to describe a set of clinical criteria that is useful, practical, and relatively simple for the clinician in describing individuals with MCI. It is important to note, however, that these are purely arbitrarily defined clinical criteria that can be challenged at either end.
The continuum outlined in Figure  1 -2 can also apply to several underlying dimensions. For example, clinical criteria can be used to describe individuals as they evolve along this course of gradual impairment. Neuropsychologically, multiple test performances can be used to characterize subjects in the setting of abnormal function of varying degrees. Memory is perhaps the neuropsychological function that has been best characterized in this fashion. Numerous memory tests are available, and an increasingly large set of normative data has been obtained to characterize various aspects of cognitive function (Ivnik et al, 1992) . Certain indices of quantitative neuroimaging can also be placed on this continuum. For example, recently rather precise volumetric measurements of temporal lobe structures have been established for individuals who are aging normally and for individuals who have had various stages of impairment ( Jack, 2003; Jack et al, 1999; Killiany et al, 2000) .
Historically, several terms have been used in the literature to describe intermediate stages of cognitive impairment. The first term to gain some degree of acceptance was benign senescent forgetfulness (Kral, 1962) , referring to what was felt to be a variant of normal aging. While some more recent literature has cast doubt on this idea, its recognition highlighted the notion that some cognitive changes are likely to be a normal part of aging. A National Institute of Mental Health work group in the mid-1980s proposed the term age-associated memory impairment to refer to memory changes with aging that, again, were felt to be a variation of normal (Crook et al, 1986) . These criteria referenced the memory function in older individuals to performance of young adults, which was problematic for the application of the term. The International Psychogeriatric Association used the term age-associated cognitive decline to encompass a variety of cognitive domains presumed to decline in normal aging (Levy, 1994) . The Canadian Study of Health and Aging coined the term cognitive impairment-no dementia, to refer to impaired cognitive function of severity insufficient to constitute dementia (Graham et al, 1997 These and other terms have been used over the years to represent an intermediate form of cognitive impairment. In recent years, MCI has come to reflect a stage of abnormal cognitive function that does not compromise activities of daily living enough to warrant the diagnosis of dementia. These patients are quite apparent to the clinician, and they have received a great deal of attention in the literature.
CLINICAL CHARACTERIZATION Criteria
The criteria for MCI outlined in Table  1 -1 have been adopted in one form or another for a variety of research studies. These criteria refer to the amnestic subtype of MCI (see below). Considerable research is being conducted to operationalize these criteria, and inconsistent use of the criteria is one of the factors that leads to the variability of outcome of studies in the literature.
The concept of MCI refers to individuals who have some cognitive impairment but are not sufficiently debilitated to warrant the diagnosis of dementia or AD. These patients are common in everyday practice, and their characterization is important for the clinician. Recent studies have indicated that these patients are likely to be at an increased risk of developing AD in the next few years; yet it is important to note that not all of them will so evolve (Larrieu et al, 2002; Ritchie et al, 2001 ). The typical scenario for an individual with MCI involves the initial development of a memory deficit followed by other cognitive abnormalities. However, other profiles can also be seen. The broadest definition of MCI would include either individuals with an impairment in a single cognitive domain that is beyond what one would expect for age or individuals with a mild degree of impairment in multiple cognitive domains. Any of these combinations are possible, and it is probably likely that all of these individuals have an increased risk of progressing to AD. The most extensive literature on this condition, however, pertains to those individuals who have only a memory impairment. Although not the only presentation of MCI, memory impairment is the best-studied and most typical presentation. Consequently, much of the subsequent discussion will focus on groups of individuals who have a memory impairment that is beyond what one would expect for age with relative preservation of other cognitive functions.
A cognitive complaint is necessary to bring the patient to the clinician's attention. Work done at Harvard University indicates that if the cognitive complaint is substantiated by an informant, it is much more likely to be reliable (Daly et al, 2000) . It is therefore essential to obtain a collateral history from an individual who knows the subject well. The normal general cognitive function criterion needs to be qualified. Frequently, patients with MCI will have significant memory impairments, to be discussed below, but also are mildly abnormal in other cognitive Another domain that is most likely to be abnormal, however, involves speeded processing and cognitive flexibility. The difficulty with incorporating this cognitive function into the definition of MCI stems from problems of measurement. Cognitive flexibility and speeded performance are likely related to prefrontal region function, and many measures can be used to assess these capacities. However, none is particularly well characterized in a normative aging sense, and consequently the precise application of instruments involving these cognitive functions is difficult. Figure 1 -3 demonstrates that statistically significant differences exist between patients with MCI and normal controls in these other domains, yet in the judgment of most clinicians these abnormalities are not of sufficient magnitude to warrant the diagnosis of dementia. While the astute clinician, no doubt, feels that these abnormalities are likely significant, one would not want to label patients as demented or having AD solely on this level of cognitive function. In addition, these deficits are not likely to be of sufficient magnitude to compromise functional abilities.
The third criterion concerns activities of daily living. Again, these patients typically function fairly independently in the community. Their forgetfulness may cause some inconvenience to them but, in general, does not compromise their overall functional ability.
The abnormal memory function for age and education is often best defined in relationship to normative neuropsychology data (Ivnik et al, 1992) . In the studies at the Mayo Clinic, memoryimpaired individuals generally scored approximately 1.5 SD below their age and education peers on indices of learning or acquisition and delayed recall . It is important to note that these persons have a mean memory impairment of 1.5 SD, which means that approximately 50% of persons will have a memory impairment of less than 1.5 SD. This degree of impairment, therefore, does not constitute a cutoff score. The most commonly used instruments for this purpose in the clinical setting include the Wechsler Memory Scale-Revised or a list-learning procedure such as the Auditory Verbal Learning Test. Figure 1 -3 also shows the relative performance of subjects with MCI on a variety of memory tests.
The memory impairment is more similar to that found in patients with AD than to the normal controls. This finding is in contrast to the top panels in Figure 1 -3 where indices of general cognitive function in the patients with MCI are more similar to the normal controls than they are to the AD patients. This general clinical profile FIGURE 1-3 Relative performance among controls, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer's disease (AD) on measures of general cognition (top two panels) and memory function (bottom two panels). The figure depicts the MCI subjects as performing more closely to the control subjects on the Mini-Mental State Examination (MMSE) and Full-Scale IQ, whereas on memory measures Logical Memory II and Visual Reproductions II, the MCI subjects perform in a similar fashion to the AD subjects. A Another domain that is most likely to be abnormal involves speeded processing and cognitive flexibility.
characterizes patients with MCI from a neuropsychological perspective.
The patients do not meet criteria for dementia by either the Diagnostic and Statistical Manual of Mental Disorders IV (American Psychiatric Association, 1994) criteria for AD or the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association Criteria (McKhann et al, 1984) . In general, their functional ability is more normal than not, and they primarily have a memory impairment.
Heterogeneity: Subtypes of Mild Cognitive Impairment
As the field of MCI research has matured, it has become apparent that other clinical patterns of MCI are likely to exist (Petersen, 2003a) . From a clinical perspective, there are at least three presentations, as shown in Figure 1 -4. The first type, known as amnestic MCI, was defined above and is described in Case 1-2. This is the typical presentation of MCI with prominent memory impairment. The second type, termed multiple-domain MCI, is characterized by a slight impairment in more than one cognitive domain but of insufficient severity to constitute dementia (Lopez et al, 2003) . The third type,
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Case 1-2
A 64-year-old woman had become aware of increasing forgetfulness in recent months. For the past year, she had been aware of lapses of recall of items she previously would have remembered easily. For example, she had an important appointment with her personal physician to discuss a medication adjustment for her osteoarthritis, which she did not keep. While anyone can forget an appointment, she noted that she had also forgotten a luncheon engagement with friends the previous week. Her close friends and family were beginning to notice these events and bring them to her attention. Otherwise, she had been handling her own finances, traveling, and driving without problems. She had difficulty identifying the onset of these symptoms, but she felt they had gradually become worse in recent months. She denied depression, stress, or other complicating medical issues. She requested an appointment with a neurologist to determine if this memory problem should be pursued further.
Comment. This woman probably has amnestic MCI. She is becoming slightly more forgetful, and this is noticeable to her family and friends. The most salient feature of the history concerns the inability to remember events in spite of putting forth a good effort. That is, while she is forgetful for incidental items, she also is starting to forget events that she is trying to remember. Meaningful information is no longer stored in an efficient manner, nor is it recalled well. This likely implicates an early disease process involving the medial temporal lobe that is presenting as an early stage of an amnestic MCI. single nonmemory domain MCI, refers to persons having a cognitive impairment in a single domain other than memory, such as executive function or language, with preservation of other cognitive skills and insufficient impairment in activities of daily living to constitute dementia. These prodromal states may progress to non-AD dementias, such as frontotemporal dementia or primary progressive aphasia.
In addition to this clinical heterogeneity, there is also etiologic heterogeneity, as shown in Figure 1 -5. Each clinical subtype can, therefore, have a variety of etiologies. For example, the most frequently studied variety of amnestic MCI is of a presumed degenerative etiology, and subjects tend to progress to AD.
Figure 1-6 characterizes the decision process for the clinician. For example, presumably the patient or family will be aware of a cognitive change and will bring this to the attention of the physician. At presentation, the physician must decide, based on a combination of the history from the patient and family members as well as a mental status examination, if there has been evidence for a cognitive decline. The physician can then determine whether the activities of daily living are relatively normal such that the person is not demented. The physician has concluded at this point that the cognitive change for this person is more than one would expect for age. As such, then the clinician has a suspicion that the person has MCI. Next, the clinician must determine the subtype of MCI and can, through office testing or possibly with the assistance of neuropsychological testing, determine whether the patient is, in fact, memory impaired for age. If this is so, and if memory is the only cognitive domain impaired, then the diagnosis is likely to be amnestic MCI. If, however, memory is impaired with one or more other cognitive domains, such as language, attention/executive function, or visuospatial skills, then the patient may have a multiple-domain MCI (Case 1-3) . Alternatively, if the subject has MCI but memory is not significantly impaired, then the clinician must determine whether a single nonmemory domain is impaired leading to single nonmemory domain MCI or whether several nonmemory domains are impaired leading to another type of multiple-domain MCI, as is shown in Figure 1 -6.
Outcome
The course of patients with MCI is becoming apparent, and many of these individuals are at an increased risk for developing AD. Using the criteria for amnestic MCI outlined above, the Mayo Alzheimer's Disease Center/Alzheimer's Disease Patient Registry followed a group of these individuals over the course of 3 to 6 years. The precise rate of progression is somewhat variable but is likely in the 10%-to 15%-per-year range. This is in distinction to incidence rates of the
KEY POINTS:
A A The precise rate of progression is somewhat variable but is likely in the 10%-to 15%-per-year range. This is in distinction to incidence rates of the development of dementia of normal older adult subjects, which are in the 1%-to 2%-per-year range. development of dementia of normal older adult subjects, which are in the 1%-to 2%-per-year range. As shown in Figure 1 -7, approximately 80% of the MCI subjects will convert to dementia by 6 years. Consequently, this group of subjects is at a greatly increased risk over the baseline population (Petersen et al, 2003c) .
The progression on the Mini-Mental State Examination, Dementia Rating Scale, and Global Deterioration Scale of these subjects on an annual basis is shown in Figure 1 A 72-year-old woman noted some difficulties with recent memory. She was starting to forget salient upcoming events like planned visits of her children. She also noted it was taking her longer to complete routine activities such as household finances. She was not making mistakes but did have to concentrate to a greater extent. Otherwise, she was doing well. She lived alone, drove, shopped, and felt she was having no other problems. She was neither depressed nor anxious and seemed quite normal to most of her friends. Her local physician ordered neuropsychological testing that showed an impairment in memory for age and slowing on complex attentional tasks. Other performance areas were well above normal. The physician referred her to a neurologist to interpret these findings.
Comment. This case likely represents a form of multiple-domain MCI. This patient's recent memory difficulties by history were corroborated on neuropsychological testing. In addition, she had noted slowing of her cognitive processes that was also demonstrated on the neuropsychological tests. Therefore, she likely has two domains involved, memory and attention, yet she is not demented. Her other cognitive and functional activities are well preserved, and she does not meet criteria for dementia. This presentation of multiple-domain MCI may progress to clinically probable AD in the future. 
MILD COGNITIVE IMPAIRMENT
" rates are compared with those for control subjects and very mild AD patients. In general, their progression rates are intermediate.
The question has been raised as to which subjects might be more likely to progress at an accelerated rate once they have been diagnosed with MCI. The Mayo Alzheimer's Disease Center data demonstrated that those individuals who were apolipoprotein E4 allele carriers were likely to progress more rapidly than noncarriers (Petersen et al, 1995) . The data also suggested that patients who performed poorly on a semantic cueing memory test might also be more likely to decline more rapidly. It should be noted, however, that this author is not recommending that clinicians use apolipoprotein E in this setting to predict who might progress more rapidly because the data are too preliminary at this time. However, the topic merits further investigation.
In a similar study, Tierney and colleagues (1996) reported findings of a group of 123 memory-impaired individuals who were not demented and had been referred by family physicians for the study. These subjects were followed for 2 years; 29 individuals developed AD while 94 did not. The authors found that a memory test for delayed recall and an index of mental control predicted who would develop AD. In their initial paper, apolipoprotein E was a reliable prognostic indicator only when combined with the memory tests.
Bowen and colleagues (1997) followed patients with an isolated memory impairment for 5 years and found that 10 of 21 subjects developed dementia over this time frame. The mean duration to dementia was 3.8 years.
Using the Global Deterioration Scale, Flicker and colleagues (1991) identified subjects with a Global Deterioration Scale of 3, which they felt represented mildly impaired subjects. Thirty-two subjects with a Global Deterioration Scale of 3 were followed over 2 years, and 23 of these individuals progressed to dementia.
More recently, Daly and colleagues (2000) have identified a cohort of individuals recruited through media advertisements as being mildly impaired but not demented. The authors have modified the Clinical Dementia Rating (CDR) to make it more sensitive at detecting individuals with a subtle memory impairment and a CDR of 0.5. Of the 123 individuals characterized in this fashion, progression to AD was 6% per year. Twenty-three of the individuals progressed over 2 years. This rate is somewhat lower than seen in other studies reported in the literature and may reflect the combination of recruitment strategy and use of the CDR as the instrument of evaluation and progression.
In a French study assessing MCI with criteria used for age-associated cognitive decline similar to those outlined earlier, Ritchie and colleagues (2001) 
KEY POINT:
A Tierney and colleagues (1996) found that a memory test for delayed recall and an index of mental control predicted who would develop AD. followed a cohort of 833 subjects longitudinally over 4 years. The investigators retrospectively applied neuropsychologically based criteria to diagnose MCI and compared the outcome of those subjects with another group meeting criteria for age-associated cognitive decline. Using this analytic technique, they felt that MCI was an unstable concept while subjects with age-associated cognitive decline actually demonstrated a higher conversion rate. The authors applied a literal interpretation of MCI criteria that were neuropsychologically based rather than using the clinical criteria that were used in other studies.
Bennett and colleagues (2002) have evaluated MCI in the Religious Orders Study. They followed a group of 211 nuns and priests with MCI involving multipledomainsofimpairmentinstead of just memory. The subjects were followed for a mean of 4.5 years and developed AD at a rate 3.1 times those subjects without a cognitive impairment.
In a study from several southwestern regions of France, Larrieu and colleagues (2002) followed a population-based sample of 1265 subjects who were at risk of developing cognitive impairment by virtue of age. They found that MCI as defined above was a good predictor of AD but that the concept was unstable over time. They found that over 2 to 3 years, 40% of the sample had reverted to normal, an observation not reported in other studies. This finding of instability may have been related to their use of the Benton Visual Retention Test (Revised) as their only memory measure. Nevertheless, this population-based study was well executed and also demonstrated that subjects with memory impairment are more likely to progress to AD.
KEY POINTS:
A Subjects in the Religious Orders Study were followed for a mean of 4.5 years and developed AD at a rate 3.1 times those subjects without a cognitive impairment.
A A study from several southwestern regions of France found that MCI was a good predictor of AD but that the concept was unstable over time. Dawe and colleagues (1992) reviewed the topic of MCI in 1992 and concluded that there was a wide discrepancy in rates of progression varying from 1% to 25%. As the previous studies indicated, this variability was likely due to a lack of consistent criteria, the use of variable neuropsychological instruments employed to measure progression, and small numbers of subjects in some of these studies.
In summary, the variability is most likely due to the specific set of criteria adopted to define subjects with MCI. As shown on the continuum in Figure  1 -2, as the criteria for MCI move to the right toward AD, the ''conversion rate'' likely increases. It is also likely that these patients are exhibiting features of very mild AD, and consequently what is being assessed is the progression of very mild AD subjects to greater degrees of impairment. However, as the criteria are shifted to the left, the group may be ''contaminated'' with normal individuals exhibiting memory changes of aging, and these subjects are less likely to progress. More consistent criteria need to be adopted to allow comparability of studies across various subject populations.
NEUROIMAGING
Recently, quantitative neuroimaging has achieved sufficient status to warrant consideration for a role in the evaluation of patients with MCI (Bobinski et al, 1999; Jack, 2003; Johnson and Albert, 2003) . Several longitudinal studies of aging and dementia have followed individuals who were previously normal and evolved to AD over the course of several years. Cross-sectional imaging studies are available on some of these subjects, and longitudinal data are being acquired. Kaye and colleagues (1997) have recently demonstrated that hippocampal volumes derived from magnetic resonance imaging (MRI) can be predictive of persons who are destined to become demented. The investigators showed that hippocampal volumes at the time of presentation were smaller in those subjects who developed dementia than in those who did not become demented. The rate of change of these two groups, however, was not different. Jack and colleagues (1997) have reported hippocampal volumes for normal older adult subjects and a group of mild AD patients. These studies, derived from large community samples, provide the foundation for the assessment of patients with MCI. In a recent longitudinal study, Jack and colleagues (1999) prediction equation has controlled for age, estrogen use, neuropsychological test performance, apolipoprotein E status, history of ischemic heart disease, and hypertension (Figure 1-9) .
In the recent imaging literature, increasing attention has been paid to measurements of the entorhinal cortex. Bobinski and colleagues (1999) measured the entorhinal cortex with MRI and felt that it was a better measure of early cognitive impairment than was the hippocampus. Killiany and colleagues (2000) also imaged the entorhinal cortex and felt that it was a better discriminatory index of the outcome of patients with a memory impairment than other measures. Xu and colleagues (2000) compared measurements of both the entorhinal cortex and hippocampal formation in the same set of control, MCI, and AD subjects and found both structures to be equally useful in terms of separating the groups of subjects. While it is quite likely that the disease process begins in the entorhinal cortex region, technical difficulties in imaging this area reliably may make the measurements somewhat less accurate. On the other hand, measurements of the hippocampal formation are quite reliable and reproducible because of better demarcation of anatomic boundaries.
Consequently the more precise measurement capability of the hippocampal formation with respect to the entorhinal cortex likely makes it currently a more attractive candidate for quantitative neuroimaging of these early transitional states.
Functional imaging studies, including single-photon emission computed tomography, have also been suggested as being useful in making this discrimination ( Johnson and Albert, 2003) . However, large groups of subjects need to be studied prospectively using this technique to establish reliability to its use.
More recently, magnetic resonance spectroscopy has been assessed as a possible tool in evaluating MCI. Kantarci and colleagues (2000) evaluated a group of subjects with MCI and compared them with normal control subjects and patients with very mild AD using myoinositol/creatine ratios and N-acetylaspartate/creatine ratios. The investigators found that the myoinositol/creatine ratio was increased in subjects with MCI relative to normal controls and also increased to a greater extent in subjects with AD relative to MCI. The N-acetylaspartate/creatine ratio did not decline, however, until the subjects had reached the stage of AD. As such, these data would suggest that the myoinositol/creatine ratio, which may be an index of glial activity, may be more useful earlier in the disease than is the N-acetylaspartate/creatine ratio, which may reflect neuronal integrity. Additional work needs to be done in this area.
The field of quantitative neuroimaging is likely to provide an adjunct to help the clinician in discriminating which subjects qualify for the diagnosis of MCI and, furthermore, which individuals might progress more rapidly than others. As more longitudinal data become available in this area, these biological parameters may increase in their utility.
NEUROPATHOLOGY
The neuropathologic substrate of patients with MCI is not known. Since patients with this level of impairment typically do not die from the disease, autopsy studies are relatively uncommon.
An important recent report from the Nun Study explored the relationship between AD neurofibrillary pathology and intermediate stages of cognitive impairment (Riley et al, 2002 A Investigators using magnetic resonance spectroscopy found that the myoinositol/ creatine ratio was increased in subjects with MCI relative to normal controls and also increased to a greater extent in subjects with AD relative to MCI.
A The neuropathologic substrate of patients with MCI is not known.
MILD COGNITIVE IMPAIRMENT
" cognitive state across the clinical spectrum, but they also noted that, by excluding other non-AD pathology, they may not be able to explain the total spectrum of findings. Approximately 50% of their total group was excluded because they had non-AD type pathology. The authors also commented that the clinical classification system used by the Nun Study may underestimate the degree of impairment in these subjects and possibly lead to difficulty in correlating the clinical picture with the neuropathologic findings. Nevertheless, this was a well-executed study that provided information on the role of neurofibrillary pathology across the clinical spectrum. It is possible that this study characterized a clinical group of subjects who were slightly more impaired than the amnestic subjects described here.
A study evaluating choline acetyltransferase activity in the hippocampus and frontal cortex of subjects from the Religious Order Study, using a classification of MCI that allowed for multiple cognitive domains to be impaired, found that 44% of the sample had low likelihood of AD pathology while another 44% had an intermediate likelihood of AD pathology according to National Institute on Aging (NIA)-Reagan Institute criteria (DeKosky et al, 2002) . This study represents the only other report in the literature characterizing a type of prospectively studied MCI subjects. However, the MCI diagnosis in the Religious Order Study was different from the current amnestic MCI criteria and allowed for impairment in multiple cognitive domains, thereby possibly including subjects who were slightly more impaired than those in the present discussion.
A study from Washington University describing the neuropathologic features of subjects with very mild AD (CDR 0.5) demonstrated that 84% of these mild subjects had the neuropathologic features of AD (Morris et al, 2001 ). This research group does not use the MCI classification and focuses on subjects with very mild clinically probable AD. In so doing, they demonstrated that when most of their mild subjects come to autopsy, the majority has features of AD neuropathologically.
Finally, a study from the Mayo Clinic on 14 subjects who died while their clinical classification was amnestic MCI demonstrated that all of the subjects had some form of medial temporal lobe pathology accounting for their memory impairment (Petersen, 2002) . Most of the subjects did not have the neuropathologic features of AD at the time of their deaths, but many had suggestive features of transition from normal aging to AD. In addition, there was some heterogeneity of the pathology, including argyrophilic grains, hippocampal sclerosis, and vascular disease.
Therefore, based on the few neuropathologic studies that have been done, it appears that MCI is not pathologically fully developed AD at this stage. Rather, the patients have pathology of their medial temporal lobes without the fully expressed features of AD. As such, this is an important stage to identify for possible intervention.
UNRESOLVED ISSUES Clinical Versus Epidemiologic Populations
The approach to defining MCI for research purposes can be quite different in clinic versus population settings. In general, in the clinic, investigators can conduct more thorough interviews of subjects and informants and can use extensive neuropsychological testing batteries. Some of the subtleties of clinical subtypes referred to earlier are difficult to discern when population studies are being conducted. in a population-based setting. Typically, out of necessity there is more reliance on neuropsychological cutoff scores and algorithmic approaches to the definition of MCI, which can lead to less reliability and stability of the diagnoses over time. In general, the clinic-based approach will give more consistent diagnoses and greater stability in longitudinal follow-up. However, the practical requirements of doing an epidemiologic survey preclude that approach in the field. Neither approach is necessarily better than the other; rather, they are designed with different goals in mind. Therefore, the studies in the literature must be interpreted in their appropriate context.
Rating Scales
The criteria outlined in Table 1 -1 constitute the most commonly accepted guidelines for MCI, but they are under consideration for revision. Occasionally, various stages on rating scales are substituted for the clinical definition of MCI (Petersen, 2000) . For example, one of the popular instruments in the field of aging and research is the CDR (Morris, 1993) , a rating scale ranging from CDR 0 (normal), to CDR 0.5 (questionable dementia), to CDR 1, 2, and 3, which constitute mild, moderate, and severe dementia, respectively. For the most part, MCI subjects will be classified as CDR 0.5. However, the CDR is a severity rating and not a diagnostic classification. Therefore, subjects with a CDR of 0.5 may have the clinical diagnosis of MCI or AD, as is shown in Figure 1 -10. The diagnosis of MCI and the CDR rating of 0.5 are not necessarily synonymous. Similarly, the Global Deterioration Scale is also used in the literature to grade the severity of dementia (Reisberg et al, 1982) . With this scale, stages 1 or 2 represent variations of normal, while stages 3 to 7 represent increasing degrees of severity of cognitive impairment. A Global Deterioration Scale stage 3 can represent either MCI or AD in a fashion similar to that of a CDR 0.5. The reader must be mindful of how the rating scales are used.
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Reference Populations
When the clinician is faced with making the distinction between cognitive changes of normal aging and MCI, he or she must be mindful of the reference population for normal. As indicated above, when age-associated memory impairment criteria were used, the older adult subjects were compared with normal young adults. Subsequent research has demonstrated that depending upon which memory test is used, up to 90% of the older adult population can be classified as ''abnormal'' when one uses young normals as the baseline reference. Another option is to measure a change in performance. While this is intuitively reasonable, most subjects do not have longitudinal cognitive data against which to compare their current performance. In addition, it is not certain what degree of change constitutes a significant decline in performance. Finally, one can use age and education norms from the population to compare current performance. This is currently done, but it also has its shortcomings. Some investigators argue that any normative population is ''contaminated'' with incipient cases of dementia thereby lowering the true normal standard of performance. Since none of these approaches is flawless, the reader needs to be aware of the reference for normal that is used in any given study.
CLINICAL TRIALS
An explosion of clinical trials in MCI has occurred in recent years. Since much of the research on aging and dementia focuses on preventing the disease before significant neuronal damage has taken place,many of the major pharmaceutical companies have trials underway in subjects with MCI (Petersen, 2003b) . None of these trials has come to completion yet, as indicated in Table 1 -2. All of the currently marketed cholinesterase inhibitors for AD are being tested, as well as antioxidants, antiinflammatories, nootropics, and glutamate receptor modulators. These trials are likely to provide important information on treatment options for the clinician with patients with MCI.
AMERICAN ACADEMY OF NEUROLOGY RECOMMENDATIONS
Three AAN practice parameter papers on dementia were published in Neurology in 2001. One of the papers dealt with management of dementia (Doody et al, 2001 ) (Appendix A), and another updated the diagnosis of dementia (Knopman et al, 2001 ) (Appendix B). The third paper addressed the detection of dementia (Petersen et al, 2001b ) (Appendix C). This paper reviewed the literature concerning MCI and made the recommendation that, while the precise outcome of the subjects is uncertain, the concept of MCI deserves attention by clinicians. These subjects appear to have an increased risk of progressing to AD in the near future and, as such, merit the attention of clinicians. Furthermore, the clinical trials for the treatment of MCI need to be monitored.
Finally, an international group of investigators reviewing the literature on MCI concluded that this is a very important group of subjects worthy of additional study. The topic is heterogeneous and merits further research to clarify its boundaries (Petersen et al, 2001a) . CONCLUSION MCI is currently receiving an increasing amount of attention in the literature. These subjects with an intermediate degree of cognitive impairment are familiar to most clinicians. They constitute a challenge for the physician insofar as precise diagnosis, outcome, and treatment options are uncertain. Nevertheless, as clinicians become increasingly aware of the criteria being considered for MCI, more information will be forthcoming.
It is important to recognize that the diagnostic criteria proposed in Table  1 -1 require the clinician's judgment. No tests or batteries of neuropsychological instruments alone will give the diagnosis. Rather, the clinician must employ these criteria in a fashion similar to making the diagnosis of AD by the Diagnostic and Statistical Manual of Mental Disorders IV (American Psychiatric Association, 1994) or by the National Institute of Neurological and Communicative Diseases and Stroke/ Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria (McKhann et al, 1984) . The challenge is to distinguish subjects from those who are experiencing cognitive changes due to other medical problems or to normal aging. Subjects with MCI do not meet clinical criteria for dementia, and consequently it is inappropriate to label them as such. However, the fact that they do have an increased risk of becoming demented in the next few years needs to be discussed with them, and if therapeutic options become available, intervention can be entertained. This is a rapidly evolving area of investigation, and more definitive criteria and treatment recommendations are likely forthcoming. Longitudinal study of patients with impaired memory in a registry of aging and dementia. Outlines criteria for age-associated memory impairment.
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